Approaches to enhance cancer radiotherapy employing gene transfer methods

Gene Therapy

Volumn 3, Issue 12, 1996, Pages 1042-1068

  Buchsbaum, D J ^a   Raben, D ^a   Stackhouse, M A ^a,b   Khazaeli, M B ^c   Rogers, B E ^a   Rosenfeld, M E ^b   Liu, T ^c   Curiel, D T ^a,b,c  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antibodies; Gene therapy; Gene transfer; Peptides; Radiation therapy; Receptors

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CELL SURFACE RECEPTOR; CYTOKINE; FLUCYTOSINE; FLUOROURACIL; GASTRIN RELEASING PEPTIDE; INTERLEUKIN 4 RECEPTOR; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PROTIRELIN RECEPTOR; RADIOISOTOPE;

BREAST CANCER; CANCER RADIOTHERAPY; CELL CYCLE; CHEMOSENSITIVITY; COMPUTER SIMULATION; DNA REPAIR; GENE INDUCTION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; COMBINED MODALITY THERAPY; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASMS;

EID: 0030473263     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (308)

1. Hwu P. The gene therapy of cancer. Principles and Practice of Oncology, PPO Updates 1995; 9: 1-13
2. Sobol RE, Scanlon KJ. The Internet Book of Gene Therapy: Cancer Therapeutics. Appleton & Lange: Stamford, 1995.
3. Dranoff G, Mulligan RC. Gene transfer as cancer therapy. Adv Immunol 1995; 58: 417-454.
4. Zhang W-W, Fujiwara T, Grimm EA, Roth JA. Advances in cancer gene therapy. Adv Pharmacol 1995; 32: 289-341.
5. Rosenberg SA et al. The development of gene therapy for the treatment of cancer. Ann Surg 1993; 218: 455-464.
6. Sobol RE, Scanlon KJ. Clinical protocols. Cancer Gene Ther 1995; 2: 225-234.
7. Sorrentino BP et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99-103.
8. McLachlin JR et al. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst 1990; 82: 1260-1263.
9. Guild BC, Mulligan RC, Gros P, Housman DE. Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc Natl Acad Sci USA 1988; 85: 1595-1599.
10. Lowe SW et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
11. Roth JA. Modulation of oncogene and tumor-suppressor gene expression: a novel strategy for cancer prevention and treatment. Ann Surg Oncol 1994; 1: 79-86.
12. Somia NV, Zoppe M, Verma IM. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA 1995; 92: 7570-7574.
13. Douglas JT, Curiel DT. Targeted gene therapy. Tumor Targeting 1995; 1: 67-84.
14. Michael SI, Hong JS, Curiel DT, Engler JA. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Therapy 1995; 2: 660-668.
15. Michael SI, Curiel DT. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Therapy 1994; 1: 223-232.
16. Vile RG Tumor-specific gene expression. Semin Cancer Biol 1994; 5: 429-436.
17. Singh SP, Lavin MF. DNA-binding protein activated by gamma radiation in human cells. Mol Cell Biol 1990; 10: 5279-5285.
18. Sukhatme VP. Early transcriptional events in cell growth: the Egr family. J Am Soc Nephrol 1990, 1: 859-866.
19. Ziff EB. Transcription factors: a new family gathers at the cAMP response site. Trends Genet 1990; 6: 69-72.
20. Sherman ML et al. Ionizing radiation regulates expression of the c-jun protooncogene. Proc Natl Acad Sci USA 1990; 87: 5663-5666.
21. Datta R et al. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 1992; 89. 10149-10153.
22. Prasad AV, Mohan N, Chandrasekar B, Meltz ML. Induction of transcription of 'immediate early genes' by low-dose ionizing radiation. Radiat Res 1995; 143: 263-272.
23. Collart FR, Horio M, Huberman E. Heterogeneity in c-jun gene expression in normal and malignant cells exposed to either ionizing radiation or hydrogen peroxide. Radiat Res 1995; 142: 188-196.
24. Brach MA et al. Ionizing radiation induces expression and binding activity of the nuclear factor kappa β. J Clin Invest 1991; 88. 691-695.
25. Woloschak GE, Chang-Liu CM, Shearin-Jones P. Regulation of protein kinase C by ionizing radiation. Cancer Res 1990; 50: 3963-3967.
26. Kim CY, Giaccia AJ, Strulovici B, Brown JM. Differential expression of protein kinase C epsilon protein in lung cancer cell lines by ionising radiation. Br J Cancer 1992; 66: 844-849.
27. Lin CS, Goldthwait DA, Samols D. Induction of transcription from the long terminal repeat of Moloney murine sarcoma pro-virus by UV-irradiation, X-irradiation, and phorbol ester. Proc Natl Acad Sci USA 1990; 87: 36-40.
28. Hallahan DE et al. Protein kinase C mediates X-ray inducibility of nuclear signal transducers EGR1 and JUN. Proc Natl Acad Sci USA 1991; 88: 2156-2160.
29. Chae HP, Jarvis LJ, Uckun FM. Role of tyrosine phosphorylation in radiation-induced activation of c-iun protooncogene in human lymphohematopoietic precursor cells. Cancer Res 1993; 53: 447-451.
30. Ishihara H, Tsuneoka K, Dimchev AB, Shikita M. Induction of the expression of the interleukin-1 beta gene in mouse spleen by ionizing radiation. Radiat Res 1993; 133: 321-326.
31. Hallahan DE, Spriggs DR, Beckett MA, Kufe DW. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA 1989; 86: 10104-10107.
32. Peter RU et al. Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res 1993; 136: 65-70.
33. Witte L et al. Effects of irradiation on the release of growth factors from cultured bovine, porcine, and human endothelial cells. Cancer Res 1989; 49: 5066-5072.
34. Pech M, Rao CD, Robbins KC, Aaronson SA. Functional identification of regulatory elements within the promoter region of platelet-derived growth factor 2. Mol Cell Biol 1989; 9: 396-405.
35. Hallahan DE et al. Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation. Cancer Res 1991; 51: 4565-4569.
36. Weichselbaum RR et al. Biological consequences of gene regulation after ionizing radiation exposure. J Natl Cancer Inst 1991; 83: 480-484.
37. Boothman DA, Bouvard I, Hughes EN. Identification and characterizaiton of X-ray-induced proteins in human cells. Cancer Res 1989; 49: 2871-2878.
38. Boothman DA, Meyers M, Fukunaga N, Lee SW. Isolation of X-ray-inducible transcripts from radioresistant human melanoma cells. Proc Natl Acad Sci USA 1993; 90: 7200-7204.
39. Fornace AJ Jr et al. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 1989; 9: 4196-4203.
40. Fukunaga N et al. Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1992; 24: 949-957.
41. Boothman DA, Lee IW, Sahijdak WM. Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: potential uses of X-ray-responsive elements for gene therapy. Radiat Res 1994; 138: S68-S71.
42. Boothman DA, Davis TW, Sahijdak WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1994; 30: 391-398.
43. Cheng X, Iliakis G. Effect of ionizing radiation on the expression of chloramphenicol acetyltransferase gene under the control of commonly used constitutive or inducible promoters. Int J Radiat Biol 1995; 67: 261-267.
44. Smith AR, Ling CC. Implementation of three dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1995; 33: 977-1343.
45. Weichselbaum RR, Hallahn DE, Sukhatme VP, Kufe DW. Gene therapy targeted by ionizing radiation. Int J Radiat Oncol Biol Phys 1992; 24: 565-567.
46. Hallahan DE, Beckett MA, Kufe D, Weichselbaum RR. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines. Int J Radiat Oncol Biol Phys 1990; 19: 69-74.
47. Hallahan DE et al. Phase I dose-escalation study of tumor necrosis factor-α and concomitant radiation therapy. Cancer J Sci Am 1995; 1: 204-209.
48. Weichselbaum RR et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994; 54: 4266-4269.
49. Weichselbaum RR et al. Ionizing radiation: a molecular switch for gene therapy. In: Sobol RE, Scanlon KJ (eds). The Internet Book of Gene Therapy: Cancer Therapeutics. Appleton & Lange: Stamford, 1995, pp 205-210.
50. Hallahan DE et al. Spatial and temporal control of gene therapy using ionizing radiation. Nature Med 1995; 1: 786-791.
51. Seung LP et al. Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res 1995; 55: 5561-5565.
52. Kim JH, Kim SH, Brown SL, Freytag SO. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSVtk gene. Cancer Res 1994; 54: 6053-6056.
53. Kim JH et al. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 1995; 33: 861-868.
54. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
55. Moolten F. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
56. Abe A et al. Transduction of a drug-sensitive toxic gene into human leukemia cell lines with a novel retroviral vector. Proc Soc Exp Biol Med 1993; 203: 354-359.
57. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 1992; 89: 33-37.
58. Elion GB et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977; 74: 5716-5720.
59. Furman PA et al. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Virology 1980; 102: 420-430.
60. Culver KW et al. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
61. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
62. Rosenfeld ME et al. Adenoviral mediated delivery of the HSV thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir. Clin Cancer Res 1995; 1: 1571-1580.
63. Wu JK et al. Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 1994; 35: 1094-1103.
64. Hwang HC et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995; 13: 7-16.
65. O'Malley BW Jr, Chen S-H, Schwartz MR, Woo SLC. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res 1995; 55: 1080-1085.
66. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-4352.
67. Ram Z et al. Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res 1994; 54: 2141-2145.
68. Huber BE et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619-4626.
69. Hamilton JM, Friedman MA. 5-FU/levamisole update. Principles and Practice of Oncology, PPO Updates 1994; 8: 1-8.
70. Lawrence TS, Maybaum J. Fluoropyrimidines as radiation sensitizers. Semin Radiat Oncol 1993; 3: 20-28.
71. Harris JD et al. Gene therapy for cancer using tumour-specific prodrug activation. Gene Therapy 1994; 1: 170-175.
72. Sorscher EJ et al. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Therapy 1994; 1: 233-238.
73. Mroz PJ, Moolten FL. Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication. Hum Gene Ther 1993; 4: 589-595.
74. Wei MX et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994; 5: 969-978.
75. Yan X et al. Effects of recombinant human γ-interferon on carcinoembryonic antigen expression of human colon cancer cells. J Immunother 1992; 11: 77-84.
76. Greiner JW et al. Intrapentoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 1992; 10: 735-746.
77. Kuhn JA et al. Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 1991; 51: 2335-2339
78. 131I-CC49) when given in combination with γ-interferon. Cancer Res 1993; 53: 600-608.
79. Cascinu S et al. Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations. Cancer Res 1993; 53: 5429-5432.
80. Borden EC, Waalen J, Schreiber R, Williams B. Response and resistance to interferons and interacting cytokines. J Natl Cancer Inst 1995; 87: 257-264.
81. Culotta E, Koshland DE Jr. DNA repair works its way to the top. Science 1994; 266: 1926-1929.
82. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995; 86: 841-854.
83. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828.
84. Minehan KJ, Bonner JA. The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of treatment. Life Sci 1993; 53: 237-242.
85. Stevnsner T, Bohr VA. Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair. Carcinogenesis 1993; 14: 1841-1850.
86. Giocanti N et al. DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 1993; 53: 2105-2111.
87. Cunningham JM et al. Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer. Br J Cancer 1991; 63: 29-36.
88. Kim JH, Kim SH, Kolozsvary A, Khil MS. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma m vivo by topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 1992; 22: 515-518.
89. Roffler SR, Chan J, Yeh M-Y. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res 1994; 54: 1276-1285.
90. Szumiel I. Ionizing radiation-induced cell death. Int J Radiat Biol 1994; 66: 329-341.
91. Nakamura K, Antoku S. Enhancement of X-ray cell killing in cultured mammalian cells by the protein phosphatase inhibitor calyculin A. Cancer Res 1994; 54: 2088-2090.
92. Katoh O et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55: 5687-5692.
93. 2-phase delay after irradiation. Radiat Res 1994; 138: S64-S67.
94. 1/S-phase transition. Radiat Res 1995; 143: 245-254.
95. 2-phase arrest in HeLa cells. Radiat Res 1995; 143: 286-292.
96. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573-582.
97. Elledge SJ, Harper JW. Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 1994; 6: 874-878.
98. Peter M, Herskowitz I. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994; 79: 181-184.
99. Muschel RJ, Zhang HB, Iliakis G, McKenna WG. Cyclin B expression in HeLa cells during the G: block induced by ionizing radiation. Cancer Res 1991; 51: 5113-5117.
100. Laderoute KR et al. Epidermal growth factor modifies cell cycle control in A431 human squamous carcinoma cells damaged by ionizing radiation. Cancer Res 1994; 54: 1407-1411.
101. Kavanagh BD, Lin P-S, Chen P, Schmidt-Ullrich RK. Radiationinduced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor. Clin Cancer Res 1995; 1: 1557-1562.
102. Jaskulski D et al. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 1988; 240: 1544-1546.
103. Freeman JW et al. Prognostic significance of proliferation associated nucleolar antigen p120 in human breast carcinoma. Cancer Res 1991; 51: 1973-1978.
104. Perlaky L et al. Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res 1992; 52: 428-436.
105. Saijo Y et al The effect of antisense p120 construct on p120 expression and cell proliferation in human breast cancer MCF-7 cells. Cancer Lett 1993; 68: 95-104.
106. Perlaky L et al. Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. Anti-Cancer Drug Des 1993; 8: 3-14.
107. Skotzko M et al. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res 1995; 55: 5493-5498.
108. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys 1993; 20: 551-567.
109. Wahl RL. Experimental radioimmunotherapy: a brief overview. Cancer 1994; 73: 989-992.
110. Knox SJ. Overview of studies on experimental radioimmunotherapy. Cancer Res 1995; 55 (Suppl.): 5832s-5836s.
111. Buchsbaum DJ. Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In: Goldenberg DM (ed). Cancer Therapy with Radiolabeled Antibodies. CRC Press: Boca Raton, 1995, pp 115-140.
112. 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996; 2: 1289-1297.
113. Welt S et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994; 12: 1561-1571.
114. Divgi CR et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995; 36: 586-592.
115. Fifth Conference on Radioimmunodetecrion and Radioimmunotherapy of Cancer. Cancer Res 1995; 55 (Suppl.): 5703s-5990s.
116. Kaminski MS et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974-1981.
117. 131I-B1 (anri-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336-340.
118. Caron PC et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994; 83: 1760-1768.
119. Waldmann TA et al. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 1995; 86: 4063-1075.
120. Goldenberg DM (ed). Cancer Therapy with Radiolabeled Antibodies. CRC Press: Boca Raton, 1995.
121. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother 1994; 15: 42-52.
122. Muraro R et al. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988; 48: 4588-4596.
123. Colcher D et al. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 1988; 48: 4597-4603.
124. Schlom J et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992; 52. 1067-1072.
125. Molthoff CF et al. Experimental and clinical analysis of the characteristics of a chimeric monoclonal antibody, MOv18, reactive with an ovarian cancer-associated antigen. J Nucl Med 1992; 33. 2000-2005.
126. 131I-chimeric B72.3 antibody therapy. Antibody, Immunoconj Radiopharm 1993; 6: 39-46.
127. Buchegger F et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med 1995; 36: 420-429.
128. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990; 31: 1035-1044.
129. Sharkey RM et al. Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 1991; 83: 627-632.
130. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52: 3402-3408.
131. 2 in patients with advanced colorectal carcinoma. Antibody Immunoconj Radiopharm 1993; 6: 239-255.
132. Milenic DE et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49 Cancer Res 1991; 51: 6363-6371.
133. 2 fragments of monoclonal antibody Mel-14. Cancer Res 1990; 50: 1822-1827.
134. King DJ et al. Improved tumor targeting with chemically crosslinked recombinant antibody fragments. Cancer Res 1994; 54: 6176-6185.
135. Rowlinson G, Snook D, Busza A, Epenetos AA. Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res 1987; 47: 6528-6531.
136. Stewart JSW et al. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncal Biol Phys 1989; 16: 405-413.
137. 2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 1990; 50: 4105-4110.
138. 90Y monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res 1989; 49: 2639-2644.
139. Quadri SM, Vriesendorp HM, Leichner PK, Williams JR. Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs. J Nucl Med 1993; 34: 938-945.
140. Buchsbaum DJ, Lawrence TS. Tumor therapy with radiolabeled monoclonal antibodies. Antibody, Immunoconj Radiopharm 1991; 4: 245-272.
141. Shrivastav S et al. Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 1989; 16: 721-729.
142. Msirikale JS, Klein JL, Schroeder J, Order SE. Radiation enhancement of radiolabelled antibody deposition in tumors. Int J Radiat Oncol Biol Phys 1987; 13: 1839-1844.
143. Kalofonos H, Rowlinson G, Epenetos AA. Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res 1990; 50: 159-163.
144. Blumenthal RD, Sharkey RM, Goldenberg DM. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression. J Natl Cancer Inst 1992; 84: 399-107.
145. Blumenthal RD, Sharkey RM, Goldenberg DM. Overcoming dose-limiting, radioantibody-induced myelotoxicity. In: Goldenberg DM (ed). Cancer Therapy with Radiolabeled Antibodies. CRC Press: Boca Raton, 1995, pp 295-314.
146. Press OW et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Engl J Med 1993; 329: 1219-1224.
147. 90Y antibody therapy of colon cancer xenografts in nude mice. Cancer Res 1990; 50 (Suppl.): 1008s-1010s.
148. Bamias A, Epenetos AA. Two-step strategies for the diagnosis and treatment of cancer with bioconjugates. Antibody, Immunoconj Radiopharm 1992; 5: 385-395.
149. Baxter LT, Yuan F, Jain RK. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res 1992; 52: 5838-5844.
150. Le Doussal J-M et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989; 30: 1358-1366.
151. Le Doussal J-M et al. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res 1990; 50: 3445-3452.
152. Le Doussal J-M et al Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med 1993; 34: 1662-1671.
153. Stickney DR et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 1991; 51: 6650-6655.
154. Goodwin DA et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988; 29: 226-234.
155. Rosebrough SF. Pharmacokinetics and biodistribution of radiolabeled avidin, srreptavidin and biotin. Nucl Med Biol 1993; 20: 663-668.
156. Peltier P et al. Radioimmunodetection of medullary thyroid cancer using a bispecific antiCEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993; 34: 1267-1273.
157. Stickney DR et al. Bifunctional antibody: ZCE/CHA 111Indium BLEDTA-IV clinical imaging in colorectal carcinoma. Antibody, Immunoconj Radiopharm 1989; 2: 1-13.
158. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991; 51: 3119-3130.
159. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987; 28: 1294-1302.
160. Khawli LA, Alauddin MM, Miller GK, Epstein AL. Improved immunotargeting of tumors with biotinylated monoclonal antibodies and radiolabeled streptavidin. Antibody, Immunoconj Radiopharm 1993; 6: 13-27.
161. van Osdol WW, Sung C, Dedrick RL, Weinstein JN. A distributed pharmacokinetic model of two-step imaging and treatment protocols, application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin. J Nucl Med 1993; 34: 1552-1564.
162. 111Inlabeled biotin. Antibody, Immunoconj Radiopharm 1993; 6: 97-109.
163. del Rosario RB, Wahl RL. Biotinylated iodo-polylysine for pretargeted radiation delivery. J Nucl Med 1993; 34: 1147-1151.
164. Paganelli G et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991; 51: 5960-5966.
165. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. New Engl J Med 1996; 334: 246-254.
166. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993; 34: 2253-2263.
167. Raben D et al. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Therapy 1996; 3: 567-580.
168. Goldenberg DM et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. New Engl J Med 1978; 298: 1384-1388.
169. 90Y-labeled monoclonal antibodies to caranoembryonic antigen. Cancer Res 1988; 48: 3270-3275.
170. Bischof-Delaloye A et al. Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med 1989; 30: 1646-1656.
171. Sharkey RM et al. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 1990; 50: 2330-2336.
172. 90Y-α-carcinoembryonic antigen monoclonal antibody. Cancer Res 1991; 51: 3802-3806.
173. Goldenberg DM. Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies. Am J Gastroenterol 1991; 86: 1392-1403.
174. Corbisiero RM et al. Comparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer: individual lesion analysis. Cancer Res 1991; 51: 5704-5711.
175. Moffatt FL JT et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. J Clin Oncol 1996; 14: 2295-2305.
176. 131I-labeled monoclonal antibodies. Cancer Res 1992; 52: 6036-6044.
177. Goldenberg DM et al. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 1993; 34: 61-70.
178. Sharkey RM et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993; 71: 2082-2096.
179. Blumenthal RD et al. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994; 54: 142-151.
180. 2 in colorectal cancer patients. Cancer 1994; 73: 850-857.
181. Behr TM et al. Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 1995; 36: 430-441.
182. Deshane J et al. Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 1995; 96: 2980-2989.
183. Rosenfeld ME et al. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med 1996; 74: 455-462.
184. Deshane J et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 1995; 59: 8-14.
185. 131I-labeled epidermal growth factor. Clin Cancer Res 1996; 2: 13-20.
186. DeNardo SJ. Radioimmunotherapy in the treatment of metastatic breast cancer: an overview. In: Goldenberg DM (ed). Cancer Therapy with Radiolabeled Antibodies. CRC Press: Boca Raton, 1995, pp 189-201.
187. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 1995; 55 (Suppl.): 5916s-5920s.
188. 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-S and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res 1995; 55 (Suppl.): 5921s-5924s.
189. Katzenellenbogen JA et al. Tumor receptor imaging. Proc Natl Cancer Inst Workshop, Review of Current Work and Prospective for Further Investigations. Clin Cancer Res 1995; 1: 921-932.
190. Miller L. Synthetic peptides come of age. J Nucl Med 1993; 34: 15N-30N.
191. Lamki LM. Tissue characterization in nuclear oncology: its time has come. J Nucl Med 1995; 36: 207-210.
192. Ashworth R et al. Visualization of the thyrotropin-releasing hormone receptor and its ligand during endocytosis and recycling. Proc Natl Acad Sci USA 1995; 92: 512-516.
193. Enzmann F et al. Structure and synthesis of the thyrotropin-releasing hormone. J Med Chem 1971; 14: 469-474.
194. Rivier J et al. Synthetic thyrotropin-releasing factor analogs. 3. Effect of replacement or modification of histidine residue on biological activity. J
195. Suzuki M et al. Synthesis and central nervous system actions of thyrotropin-releasing hormone analogues containing a dihydroorotic acid moiety. J Med Chem 1990; 33: 2130-2137.
196. Szirtes T, Kisfaludy L, Palosi E, Szporny L. Synthesis of thyrotropin-releasing hormone analogues. 1. Complete dissociation of central nervous system effects from thyrotropin-releasing activity. J Med Chem 1984; 27: 741-745.
197. Chang J-K et al. Synthesis of analogs of the thyrotropin-releasing hormone and structure-activity relationships. J Med Chem 1971; 14: 484-487.
198. Sievertsson H et al. Thyrotropin and prolactin inhibitory studies by compounds related to the thyrotropin releasing hormone. Biochem Biophys Res Comm 1975; 66: 1401-1407.
199. Coy DH et al. Synthesis and biological properties of the 2-L-β-(pyrazolyl-1)alanine analogs of luteinizing hormone-releasing hormone and thyrotropin-releasing hormone. J Med Chem 1975; 18: 948-949.
200. 2: a synthetic analogue with specific activity greater than that of TRF. Endocrinology 1971; 89: 1485-1488.
201. Sievertsson H, Chang J-K, Folkers K, Bowers CY. On the role of the histidine moiety in the structure of the thyrotropin-releasing hormone. J Med Chem 1972; 15: 219-221.
202. Falck-Pedersen E et al. Expression of thyrotropin-releasing hormone receptors by adenovirus-mediated gene transfer reveals that thyrotropin-releasing hormone desensitization is cell specific. Mol Pharmacol 1994; 45: 684-689.
203. Raben D et al. Strategies to augment radioimmunotherapy via genetic induction of receptors for radioligand binding. Cancer Gene Ther 1995; 2: 330.
204. Mosley B et al. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 1989; 59: 335-348.
205. Paul WE. Interleukin-4: a protorypic immunoregulatory lymphokine. Blood 1991; 77: 1859-1870.
206. Curiel DT. High-efficiency gene transfer employing adenovirus-polylysine-DNA complexes. Nat Immun 1994; 13: 141-164
207. Battey JF et al. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells. Proc Natl Acad Sci USA 1991; 88: 395-399.
208. Corjay MH et al. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells. J Biol Chem 1991; 266: 18771-18779.
209. Frankel A, Tsao M-S, Viallet J. Receptor subtype expression and responsiveness to bombesin in cultured human bronchial epithelial cells. Cancer Res 1994; 54: 1613-1616.
210. Moustafa A-EA, Tsao M-S, Battey JF, Viallet J. Expression of the gastrin-releasing peptide receptor confers a growth response to bombesin in immortalized human bronchial epithelial cells. Cancer Res 1995; 55: 1853-1855.
211. Davis TP et al. Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists. Peptides 1992; 13: 401-407.
212. Moody TW, Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci 1993; 52: 1161-1173.
213. Coy DH et al. Systematic development of bombesin/gastrin-releasing peptide antagonists. J Natl Cancer Inst Monogr 1992; 13: 133-139.
214. Heimbrook DC et al. Gastrin-releasing peptide antagonists with improved potency and stability. J Med Chem 1991; 34: 2102-2107.
215. Rivier JE, Brown MR. Bombesin, bombesin analogues, and related peptides: effects on thermoregulation. Biochemistry 1978; 17: 1766-1771.
216. Hoffman TJ, Sieckman GL, Volkert WA. Targeting small cell lung cancer using iodinated peptide analogs. J Labelled Compd Radiopharm 1995; 37: 321-323.
217. Zalutsky MR, Narula AS. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Appl Radiat Iso 1987; 38: 1051-1055.
218. Lamberts SWJ et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab 1990; 71: 566-574.
219. 3]-octreoride: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-731.
220. Woltering EA, O'Dorisio MS, O'Dorisia TM. The role of radio-labeled somatostatin analogs in the management of cancer patients. Principles and Practice of Oncology, PPO Updates 1995; 9: 1-16.
221. 111In-DTPA-D-Phe']-octreoride, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991; 49: 1583-1591.
222. Krenning EP et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 33: 652-658.
223. Lamberts SW, Bakker WH, Reubi J-C, Krenning EP. Somatostatin receptor imaging. In vivo localization of tumors with a radiolabeled somatostatin analog. J Steroid Biochem Mol Biol 1990; 37: 1079-1082.
224. 1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 1991; 49: 1593-1601.
225. Anderson CJ et al. In vitro and in vivo evaluation of copper-64-octreoride conjugates. J Nucl Med 1995; 36: 2315-2325.
226. Smith-Jones PM et al. Synthesis, radioiabelling, and evaluation of DTPA/octreotide conjugates for radiotherapy. J Labelled Compd Radiopharm 1995; 37: 499-501.
227. Deshpande SV et al. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990; 31: 473-479.
228. 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer 1996; 65: 1-8.
229. Blum AM et al. Murine mucosal T cells have VLP receptors functionally distinct from those on intestinal epithelial cells. J Neuroimmunol 1992; 39: 101-108.
230. Ottaway CA. In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells. J Exp Med 1984; 160: 1054-1069.
231. Virgolini I et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 1994; 54: 690-700.
232. Paul S, Said SI. Characterization of receptors for vasoactive intestinal peptide solubilized from the lung. J Biol Chem 1987; 262: 158-162.
233. Sreedharan SP, Patel DR, Huang J-X, Goetzl EJ. Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem Biophys Res Comm 1993; 193: 546-553.
234. Virgolini I et al. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 1995; 36: 1732-1739.
235. Virgolini I et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. New Engl J Med 1994; 331: 1116-1121.
236. Fleming TP et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992; 52: 4550-4553.
237. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.
238. Moscatello DK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55: 5536-5539.
239. Kalofonos HP et al. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 1989; 30: 1636-1645.
240. Brady LW et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1991; 22: 225-230.
241. Rakowicz-Szulczynska EM, Otwiaska D, Rodeck U, Koprowski H. Epidermal growth factor (EGF) and monoclonal antibody to cell surface EGF receptor bind to the same chromatin receptor. Arch Biachem Biophys 1989; 268: 456-464.
242. Savage CR Jr, Inagami T, Cohen S. The primary structure of epidermal growth factor. J Biol Chem 1972; 247: 7612-7621.
243. Wikstrand CJ et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55: 3140-3148.
244. Reist CJ et al. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 1995; 55: 4375-4382.
245. Mausner LF, Srivastava SC. Selection of radionuclides for radioimmunotherapy. Med Phys 1993; 20: 503-509.
246. Bradley EW, Chan PC, Adelstein SJ. The radiotoxicity of I-125 in mammalian cells. I. Effects on the survival curve of radioiodine incorporated into DNA. Radiat Res 1975; 64: 555-563.
247. Chan PC, Lisco E, Lisco H, Adelstem SJ. The radiotoxicity of I-125 in mammalian cells. II. A comparative study on cell survival and cytogenetic responses to IUdR-125, IUdR-131, and HTdR-3. Radiat Res 1976; 67: 332-343.
248. Adelstein SJ, Kassis AI. Radiobiologic implications of the microscopic distribution of energy from radionuclides. Nucl Med Biol 1987; 14: 165-169.
249. Kassis AI et al. Lethality of Auger electrons from the decay of Bromine-77 in the DNA of mammalian cells. Radiat Res 1982; 90: 362-373.
250. Humm JL, Chin LM. A model of cell inactivation by alpha-particle internal emitters. Radiat Res 1993; 134: 143-150.
251. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984; 11: 638-645.
252. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988; 48: 7022-7032.
253. 2, and Fab in tumors. Cancer Res 1989; 49: 5656-5663.
254. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990; 9: 253-266.
255. Jain RK. Haemodynamic and transport barriers to the treatment of solid rumours. Int J Radiat Biol 1991; 60. 85-100.
256. Andrew SM et al. Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM1899). Cancer Res 1990; 50: 5225-5230.
257. Goldenberg DM, Blumenthal RD, Sharkey RM. Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin Cancer Biol 1990; 1: 217-225.
258. Sands H et al. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res 1988; 48: 188-193.
259. Sung C et al. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 1992; 52: 377-384.
260. Jones PL, Gallagher BM, Sands H. Autoradiographic analysis of monoclonal antibody distribution in human colon and breast tumor xenografts. Cancer Immunol Immunother 1986; 22: 139-143.
261. 2 fragments in human rumour xenografts: an autoradiographic and imrnunohistochemical study. Int J Cancer 1988; 3 (Suppl.): 23-29.
262. Ong GK, Mattes MJ. Penetration and binding of antibodies in experimental human solid tumors grown in mice. Cancer Res 1989, 49: 4264-4273
263. 131I-9.2.27 monoclonal antibody in human malignant melanoma. Cancer Res 1989; 49: 2783-2789.
264. Blumenthal RD et al. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol Immunother 1991; 33: 351-358.
265. Shockley TR et al. Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res 1992; 52: 367-376.
266. Buchsbaum DJ, Lawrence TS. New trends in the use of radioimmunoconjugates for the therapy of cancer. In: Rodwell J (ed). Targeted Diagnosis and Therapy. Marcel Dekker: New York, 1990, pp 215-255.
267. Bigler RE, Zanzonico PB. Adjuvant radioimmunotherapy for micrometastases. In: Srivastava SC (ed). Radiolabeled Monoclonal Antibodies for Imaging and Therapy. Plenum Press: New York, 1987, pp 409-428.
268. Wilbur DS. Potential use of alpha emitting radionuclides in the treatment of cancer. Antibody, Immunoconj Radiopharm 1991; 4: 85-97.
269. Kassis AI et al. The in vitro radiobiology of astatine-211 decay. Radiat Res 1986; 105: 27-36.
270. 212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-partide-emitter radioimmunotherapy. J Natl Cancer Inst 1988; 80: 449-452.
271. Mitchell JB, Bedford JS, Bailey SM. Dose-rate effects in plateauphase cultures of S3 HeLa and V79 cells. Radiat Res 1979; 79: 552-567.
272. Hall E. Radiobiology for the Radiologist. 4th edn. JB Lippincott: Philadelphia, 1994, pp 121-125.
273. Williams JR, Zhang YG, Dillehay LE. Sensitization processes in human tumor cells during protracted irradiation: possible exploitation in the clinic. Int J Radiat Oncol Biol Phys 1992; 24: 699-704.
274. Hall E. Radiobiology for the Radiologist. 4th edn. JB Lippincott: Philadelphia, 1994, pp 153-164.
275. 90Y. Int J Radiat Oncol Biol Phys 1984; 10: 341-348.
276. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases. Cancer Res 1990; 50: 2963-2967.
277. Zalutsky MR et al. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res 1994; 54: 4719-4725.
278. Macklis RM et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 1988; 240: 1024-1026.
279. Kozak RW et al. Bi-212-labeled anti-TAC monoclonal antibody: a particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci USA 1986; 83: 474-478.
280. Brown I. Astatine-211: its possible applications in cancer therapy. Appl Radiat Iso 1986; 37: 789-798.
281. Roeske JC et al Modeling of doses to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. Int J Radiat Oncol Biol Phys 1990; 19: 1539-1548.
282. Sung C et al. Streptavidin distribution in metastaric tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res 1994; 54: 2166-2175.
283. Sung C, van Osdol WW. Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding. J Nucl Med 1995; 36: 867-876.
284. Saga T et al. Two-step targeting of experimental lung metastases with biotinylated antibody and radiolabeled Streptavidin. Cancer Res 1994; 54: 2160-2165.
285. Liu T et al. A simulation study of tumor-specific delivery of radioligand through genetically induced avidin-biotin system. Proc Joint Stat Meetings. Orlando, FL, 1995.
286. Ledley TS, Ledley FD. Multicompartment, numerical model of cellular events in the pharmacokinetics of gene therapies. Hum Gene Ther 1994; 5: 679-691.
287. Nabel GJ et al. Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 1994; 5: 57-77.
288. Zhang W-W, Roth JA. Anti-oncogene and tumor suppressor gene therapy examples from a lung cancer animal model. In Vivo 1994; 8: 755-769.
289. Fujiwara T et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-1462.
290. Chen S-H et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92: 2577-2581.
291. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990, 50: 7745-7749.
292. 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo. Radiat Res 1992; 132: 351-358.
293. Wilder RB et al. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Int J Radiat Oncol Biol Phys 1993; 28: 119-126.
294. Carver RI Jr et al. Strategy for achieving selective killing of carcinomas. Gene Therapy 1994; 1: 46-50.
295. DiMaio JM et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vino. Surgery 1994; 116: 205-213.
296. Osaki T et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994; 54: 5258-5261
297. Manome Y et al. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res 1994; 54. 5408-5413.
298. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995; 6: 881-893.
299. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res 1993; 53. 962-967.
300. Vile RG, Hart IR. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993; 53: 3860-3864.
301. Hughes BW et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 1995; 55: 3339-3345.
302. Ido A et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res 1995; 55: 3105-3109.
303. Blumenthal RD et al. Physiological factors influencing radioantibody uptake: a study of four human colonic carcinomas. Int J Cancer 1992; 52: 1-7.
304. Tang D-C, Johnston SA, Carbone DP. Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors. Cancer Gene Ther 1994; 1: 15-20.
305. Goldsmith KT, Curiel DT, Engler JA, Carver RI Jr. Transcomplementation of an E1A-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells. Hum Gene Ther 1994; 5: 1341-1348.
306. Scaria A, Curiel DT, Kay MA. Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes. Gene Therapy 1995; 2: 295-298.
307. Thierry AR et al. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 1995; 92: 9742-9746.
308. Zhu N, Liggitt D, Liu Y, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993; 261: 209-211.